SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A strong third-quarter report and raised revenue outlook, driven by demand for Mounjaro and Zepbound, are fueling Lillys breakout and a wave of analyst upgrades. Traders are also weighing the growth outlook against a lower profit forecast tied to acquisition-related R&D charges, weaker-than-expected Foundayo sales and concerns about valuation.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders weigh Middle East supply risksespecially reported attacks and threats around the Strait of Hormuzagainst possible US-Iran negotiations that could ease oil prices. Bulls cite disrupted flows and escalation risks, while bears argue that a deal or de-escalation could quickly unwind the geopolitical premium.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake is drawing attention as traders await the FDAs decision on whether to accept its sonelokimab application for hidradenitis suppurativa and what review timeline it will receive. The community is split between optimism about the drug and upcoming regulatory milestone and concern over approval risk, commercialization plans, and continued weakness in biotech shares.

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

Clorox Co.

Cloroxs steep decline has fueled debate over its turnaround, with investors split between buying the beaten-down dividend stock and worrying about weak sales, execution and dividend sustainability. Upcoming quarterly results and the incoming CEOs ability to revive growth are also in focus.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is drawing attention ahead of its quarterly report, with traders weighing whether guidance can hold against concerns about its Caremark PBM business and Aetnas Medicare Advantage outlook. Some see an undervalued, defensive healthcare business, while others remain wary of the operating and reimbursement pressures.

Wells Fargo & Co. is a diversified and community-based financial services company, which engages in the provision of banking, insurance, investments, mortgage, and consumer and commercial finance products and services. It operates through the following segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth and Investment Management. The Consumer Banking and Lending segment offers consumer and small business banking, home lending, credit cards, auto, and personal lending. The Commercial Banking segment provides banking and credit products across industry sectors and municipalities, secured lending and lease products, and treasury management. The Corporate and Investment Banking segment is composed of corporate banking, investment banking, treasury management, commercial real estate lending and servicing, and equity and fixed income solutions, as well as sales, trading, and research capabilities. The Wealth and Investment Management segment refers to personalized wealth management, brokerage, financial planning, lending, private banking, trust, and fiduciary products and services. The company was founded by Henry Wells and William G. Fargo on March 18, 1852 and is headquartered in San Francisco, CA.

Wells Fargo & Co.

Wells Fargos Q3 results are driving attention: earnings topped expectations, but a revenue and net interest income shortfall, alongside higher loan-loss provisions, weighed on shares. Traders are split between concern over lending trends and the view that profit growth and healthy business activity remain supportive.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Schwab and thinkorswim platform outages are drawing attention, with many users reporting login problems, inaccurate quotes, and inability to place or manage trades. Frustration is widespread, and some traders say the recurring reliability issues are prompting them to consider moving to other brokerages.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is falling with semiconductor and technology stocks as Intels weak outlook and broader doubts about AI infrastructure spending and returns pressure the sector ahead of AMDs earnings. Traders debate whether the move is sympathy sellingwith some arguing Intels struggles could benefit AMDor a warning about stretched valuations and cooling AI expectations.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs October deliveries rose month over month, prompting debate over whether the growth can support its ambitious fourth-quarter delivery pace. Bulls see the delivery trend as evidence of demand, while skeptics remain focused on uncertainty around guidance and the stocks prolonged decline.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Discussion is dominated by GameStop warrants reportedly expiring worthless, with traders split over whether that removes a dilution overhang or leaves warrant holders with losses and reflects poorly on management. Speculation about Roaring Kittys changed X profile and a possible return is adding excitement, but no return is confirmed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline

Mentari Therapeutics secures $200 million in private financing before merging with InMed Pharmaceuticals to fund migraine therapies.read more...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

InMed Pharmaceuticals (NASDAQ:INM) stock moved upwards by 66.8% to $2.57 during Wednesday's pre-market session. The company's market cap stands at $8.2 million.
China SXT Pharmaceuticals (NASDAQ:SXTC)read more...

$490 Million Biotech Bet: Mentari Therapeutics Strengthens Migraine Pipeline Ahead of Nasdaq Merger

Mentari Therapeutics is making a major statement in the biotechnology sector, announcing a $200 million private placement that, when combined with its previously announced $290 million financing, brings total committed capital to approximately $490 million ahead of its planned merger with InMed Pharmaceuticals (NASDAQ:INM). The financing underscores growing investor interest in next-generation migraine therapies and provides the company with substantial resources to advance its clinical pipeline over the coming years.

Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline

Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline PR Newswire WALTHAM, Mass., July 22, 2026 WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics...

Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders?

Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders? Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 6, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--NIMU, INM, OLN, and HUN

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--NIMU, INM, OLN, and HUN $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--NIMU, INM, OLN, and HUN PR Newswire NEW YORK, July 6, 2026 NEW YORK, July 6, 2026 /PRNewswire/ -- Class Action...

Are GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders?

Are GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders? Are GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 12, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders?

Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders? Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 28, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INM

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INM SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INM PR Newswire NEW YORK, May 28, 2026 NEW YORK, May 28, 2026 /PRNewswire/ -- Class Action...

These Stocks are Riding Some of the Hottest Narratives on Wall Street

Here are today’s most compelling market narratives. $NTHI, $AMST, $MTVA, $AGYS, $INM, $CODX

InMed Pharmaceuticals, Inc. is a pharmaceutical drug development company, which engages in developing small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

InMed Pharmaceuticals Inc

Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise

Equity

Bullish Sentiment

Shares of InMed Pharmaceuticals surged to levels not seen in nearly five months, capturing significant attention from retail investors.&nbsp;The biopharma company, with a market cap of just under $4 million, announced on Tuesday that its INM-901 small molecule drug candidate for Alzheimer's disease demonstrated promising results in a recent clinical trial.The study showed that INM-901 significantly reduced several markers of neuroinflammation, both in plasma and the brain.&nbsp;Specifically, the high-dose treated group exhibited a dose-dependent reduction in pro-inflammatory cytokines and neurofilament light chain levels in the plasma.&nbsp;Additionally, the trial indicated a reduction in key neuroinflammatory genes in the brain, signaling a potential breakthrough in Alzheimer's treatment.Eric Hsu, InMed's Senior Vice President of Preclinical R&amp;D, expressed excitement over the results, noting, "The ability of INM-901 to actively reduce inflammation is an exciting development, as neuroinflammation has emerged as a promising new drug target beyond existing AD treatments focused primarily on removing amyloid beta plaques and tau protein tangles."&nbsp;He added, "INM-901 may address multiple pathological factors, making it a very promising drug candidate."The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform.&nbsp;One user expressed happiness with the stock's surge and speculated on the potential for a buy-out.<stembedurl>https://stocktwits.com/pennyman/message/600871159</stembedurl>Another suggested that InMed's current levels were too good an entry point to miss.<stembedurl>https://stocktwits.com/AmbushPredator/message/600878277</stembedurl>According to Koyfin data, InMed has only about 718,000 shares outstanding and a short interest of 1.3%.&nbsp;While <a href="https://stocktwits.com/symbol/INM">InMed's stock</a> is down nearly 30% over the past 12 months, it has gained approximately 14% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform. 

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.60
Prev Close	$1.63
Open	$1.55
Dividend Yield	0.00%
50-Day Moving Average	$1.38
Beta	0.92
Avg. Volume	64,590.73
PE Ratio	-0.51

52-Week High	$2.33
52-Week Low	$0.575
Market Capitalization	$8.79M
EPS (Annual)	-$3.12
Price to Book	7.95
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

INM Fundamentals